MIB Agents OsteoBites

Osteosarcoma Webinar Series: Keri Schadler, PhD and Kiri Ness, PT, PhD, FAPTA will partner to provide information about the importance of exercise for patients undergoing treatment as well as long term survivors of osteosarcoma. Together, they will provide a clinical perspective as well as an overview of the latest evidence that documents the need for and the initial success of exercise intervention during and after treatment for cancer. Dr. Schadler is an Associate Professor in the Department of Pediatrics at MD Anderson Cancer Center. Her lab utilizes mouse models and collaborations with clinical investigators to delineate the multi-faceted effects of exercise on the tumor microenvironment. Specifically, the Schadler lab aims to understand how exercise changes cellular and molecular signaling within the tumor vasculature and immune cells, and to use exercise as a tool to enhance tumor response to standard therapies. Dr. Ness is a physical therapist and clinical epidemiologist whose research focuses on the late effects of childhood and adolescent cancer and its treatment. She has a particular interest in human movement and performance, designing interventions to prevent functional loss during therapy or remediate impairment following curative treatment. She has over 350 peer reviewed original research papers and has had continuous funding to support her work since 2005. She is the MPI of the St. Jude Lifetime Cohort and PI of the Human Performance Laboratory at St. Jude Children's Research Hospital.

Debra L. Friedman, M.D., is a professor of Pediatrics in the Division of Hematology and Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt. She is the E. Bronson Ingram Chair of Pediatric Oncology and the leader of the Cancer Control and Prevention Program and directs the Cancer Survivorship programs at the Vanderbilt-Ingram Cancer Center. Dr. Friedman's research interests lie in the long term outcomes for cancer survivors, as well as in the design of novel therapeutic protocols for childhood cancer, designed to decrease adverse long-term effects of therapy. She has leadership roles in Children's Oncology Group (COG) and is an internationally recognized expert in cancer survivorship, participating in projects evaluating best practices and models of care. She is investigating a diverse group of physiologic and psychosocial outcomes among survivors of pediatric cancer, hematopoietic stem cell transplant and medical oncology. Friedman completed her pediatric residency and a joint fellowship in Pediatric Hematology/Oncology and Cancer Epidemiology at the University of Pennsylvania and The Children's Hospital of Philadelphia (CHOP). Prior to coming to Vanderbilt in 2008, she served as the co-director of the Cancer Survivorship Program at CHOP and then, as the founder and director of the Fred Hutchinson Cancer Research Center Survivorship Program. ---- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Joshua Nash is a PhD candidate under Dr. Adam Shlien at The Hospital for Sick Children in Toronto, Canada. Joshua's research focuses on leveraging transcriptomics and machine learning to understand the overarching biology of sarcomas and mesenchymal tumours and to develop more molecularly informed and prognosticating diagnostic subtypes. -- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Ming Li, PhD, is Member of the Immunology Program at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell Graduate School of Medical Sciences. His laboratory studies immune regulation and its relevance to diseases including cancer. Recent work has focused on the signaling, metabolic, and transcriptional mechanisms of T cell regulation as well as tumor-elicited innate and adaptive immune responses, and how this knowledge can be translated for novel cancer immunotherapy. Dr. Li received his PhD in Biological Sciences from Columbia University, and postdoctoral training at Yale University. Dr. Li is an American Academy of Arts and Sciences (AAAS) Fellow and has received a number of honors including a Howard Hughes Medical Institute (HHMI) Faculty Scholar Award, a Rita Allen Foundation Scholar Award, an American Cancer Society Scholar award, and the 2016 American Association of Immunologists (AAI)-BD Bioscience Investigator Award for outstanding contributions to the field of immunology. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

In this episode, OsteoWarriors Camille and Mia interview three long term osteosarcoma survivors.  Hear from Maeve, Sloane, and Eva about their osteosarcoma stories, what the most difficult hurdles have been for them, and what advice they would give themselves if they could go back in time.  While osteosarcoma is a tough journey for most patients, this episode will fill you with hope. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Nilay Shah, MD is a clinician-scientist and Associate Professor in the Division of Hematology/Oncology/BMT at Nationwide Children’s Hospital. His primary clinical focus is on pediatric solid tumors, including neuroblastomas, tumors of the kidneys, and rare solid tumors of childhood. His research focuses on the molecular drivers of pediatric cancers and how new treatment approaches can be taken to better target those drivers. In this role, he works to identify new uses of currently available anticancer treatments, including drugs originally developed for use against cancers in adults. He serves as Associate Director for Liver Tumor, Kidney Tumor, Germ Cell, and Neuroblastoma Targeted Therapies, and is currently the Sponsor and Study Principal Investigator the CaboMain trial, a Phase 2 study evaluating the efficacy of the oral anticancer agent cabozantinib as a maintenance therapy for ultra-high-risk solid tumors. He also serves as co-director of the Cancer Genetics Program. This program serves to advance the use of genetic and genomic evaluations for the benefits of patients. In this role, he sees patients in the Cancer Predisposition Clinic for evaluation, surveillance, and management of patients with genetic alterations that predispose to cancer development. He also consults on patients for precision oncology, partnering with the Institute for Genomic Medicine to identify therapeutic approaches based on patient tumor and germline genomics. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

In this episode, OsteoWarriors Camille and Mia share songs that have resonated with them during their life with cancer. Find out why Fight Song is not their preferred anthem for AYA cancer patients and why hope can feel like a four letter word. Listen in as they break down lyrics, discuss why osteosarcoma is like a masochistic toxic ex, and examine how music can heal and help validate the feelings and emotions that AYA cancer patients deal with. You can also listen to these meaningful musical selections on a special Spotify playlist by copying and pasting the link here into your web browser, or scanning the QR code : https://open.spotify.com/playlist/6ARr8egX2vQ23Aql1ypSb5?si=0d1d2abf6da44cb5 --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

OsteoBites Preguntas & Respuestas con Nino Rainusso, MD: Únase a nosotros para un episodio especial de OsteoBites en español. Nino Rainusso, MD del Texas Children's Hospital con preguntas de respuesta sobre el osteosarcoma de pacientes y cuidadores. El Dr. Nino Rainusso es miembro del equipo de tumores sólidos pediátricos y codirector del programa de cardiooncología del Texas Children's Hospital - Baylor College of Medicine. Su laboratorio se centra en comprender el papel de las células madre cancerosas (CSC) tanto en el desarrollo de tumores como en la resistencia a la quimioterapia en sarcomas pediátricos. Ha realizado varios estudios destinados a caracterizar las CSC en tumores óseos pediátricos. Han desarrollado varios modelos de xenoinjerto derivado de paciente (PDX) de osteosarcoma, sarcoma de Ewing, rabdomiosarcoma y sarcomas de tejidos blandos. Su laboratorio participa actualmente en un proyecto PDX multiinstitucional destinado a caracterizar y evaluar el impacto de nuevos enfoques terapéuticos en cánceres pediátricos que utilizan PDX. Dr. Nino Rainusso is a member of the Pediatric Solid Tumor Team and Co-Director of the Cardio-Oncology Program at Texas Children’s Hospital - Baylor College of Medicine. Their laboratory focuses on understanding the role of cancer stem cells (CSCs) in both tumor development and chemotherapy resistance in pediatric sarcomas. He has conducted several studies aimed to characterize CSCs in pediatric bone tumors. They have developed several patient-derived xenograft (PDX) models of osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and soft-tissue sarcomas. Their laboratory currently participates in a multi-institutional PDX project aimed to characterize and to evaluate the impact of novel therapeutic approaches in pediatric cancers using PDXs. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

TCF-001 TRACK is a patient advocacy initiated, decentralized clinical trial enrolling patients with rare cancers and cancer of unknown primary. Patients can enroll remotely without a requirement to travel, and enrolled patients receive biomarker testing of tissue and blood at no cost, as well as treatment recommendations from a virtual molecular tumor board. This presentation will provide details on how TRACK works, and how it seeks to achieve its goals of providing patients with personalized, potentially actionable information while simultaneously generating critical research data. Jim Palma is the Executive Director of TargetCancer Foundation. Since joining TargetCancer Foundation in 2010, Jim has overseen its growth from a small start-up to a nationally recognized foundation supporting comprehensive rare cancer research programs and patient support services. Prior to joining TargetCancer Foundation, he spent eleven years at Fidelity Investments in Boston, MA. Jim is a member of the Board of Directors of the National Organization for Rare Disorders (NORD), and is a founding Co-Chair of the NORD Rare Cancers Coalition. In addition, Jim is a Steering Committee member at the GI Cancers Alliance and the Global Cholangiocarcinoma Alliance. Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University, and received his B.A. from Loyola University Maryland. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Matteo Trucco, MD and Kurt Weiss, MD joins us on OsteoBites to describe the collaboration that led to the current Phase 1 clinical trial repurposing the alcoholism drug disulfiram to see if it can overcome the chemotherapy resistance seen in relapsed sarcomas, including osteosarcoma. Matteo Trucco is a Pediatric Oncologist and the Clinical Director of Pediatric Hematology/Oncology at Cleveland Clinic Children’s, specializing in the care of children, teenagers and young adults battling bone and soft tissue cancers. He also directs the Children’s Cancer Innovative Therapy Program where he and colleagues design, develop and conduct clinical trials seeking more effective and less toxic treatments for childhood cancers. Dr. Trucco earned his undergraduate degree from the University of Pennsylvania and Medical Degree from Temple University School of Medicine. He completed his Pediatrics Residency at Rainbow Babies and Children’s Hospital and his Pediatric Hematology/Oncology Fellowship from Johns Hopkins and the National Cancer Institute. In addition to his roles at the Cleveland Clinic, he is a Co-chair of the National Pediatric Cancer Foundation’s Sunshine Project consortium, partnering with other top pediatric cancer centers to develop clinical trials. He is honored to be on the Board of MIB Agents, chairs its Scientific Advisory Board and co-chairs the organizing committee for the FACTOR Conference. He also has the privilege of moderating the MIB Agents TURBO Tumor Review Board for Osteosarcoma. Dr. Weiss directs the Department’s Musculoskeletal Oncology Laboratory, a basic science laboratory dedicated to the study of sarcomas. His mission is to help develop a world-class translational sarcoma research program at the University of Pittsburgh. As a bone cancer survivor himself, Dr. Weiss brings passion and enthusiasm to the laboratory, clinic, and operating room. Through the UPMC Hillman Cancer Center, he is also a proud collaborator with scientists who are trying to understand how other forms of cancer spread to and destroy the bone. Dr. Weiss is a Founding Member of the Musculoskeletal Oncology Research Initiative (MORI), Pittsburgh Cure Sarcoma (PCS), the Pittsburgh Sarcoma Research Collaborative (PSaRC), and the Pittsburgh Center for Bone and Mineral Research (PCBMR). He is a peer reviewer for multiple journals including the Journal of the American Academy of Orthopaedic Surgeons, BioMed Central Cancer, Sarcoma, Cancer Research, International Journal of Cancer, and others. He is a former member of the NIH’s Center for Scientific Review Early Career Reviewer program. He has served on multiple National Cancer Institute Study Sections. He is a member of the Musculoskeletal Tumor Society (MSTS) for which he serves as Chair of the Research Committee and the Connective Tissue Oncology Society (CTOS), for which he has served on the Board of Directors. ----- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Listen in this month as Mia and Sloane have a gab sesh about the daily interactions and challenges as an AYA living with cancer that get under their skin. Hear their thoughts on why there is a lot of room for improvement on Hollywood's representation of pediatric cancer patients, how cancer limits participation in a society that doesn't address the needs of people with disabilities, the difficulties around sharing their cancer story, the cliche of being brave, and why they wish there was an off button for snapchat memories. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Dr. Fiona Freeman is an Assistant Professor in the School of Mechanical and Materials Engineering at University College Dublin (UCD). She graduated in Biomedical Engineering in 2011 and earned her PhD from the University of Galway in 2016, focusing on developing new strategies for bone tissue regeneration. Afterward, Dr. Freeman was awarded two prestigious postdoctoral fellowships: the Government of Ireland IRC Postdoctoral Research Fellowship and the Marie Skłodowska-Curie Global Fellowship. These fellowships provided her with opportunities to work as a postdoctoral researcher in renowned labs at Massachusetts Institute of Technology (MIT), Brigham and Women's Hospital, Johns Hopkins University, and Trinity College Dublin. In September 2022, Dr. Freeman was appointed as the first Ad Astra fellow in the School of Mechanical and Materials Engineering. Her current research focuses on using innovative engineering techniques to gain a better understanding of and develop novel therapeutics for treating osteosarcoma, a paediatric bone cancer. As part of her research, Dr. Freeman identified a novel microRNA, miR-29b, as a potential therapeutic target for osteosarcoma. She formulated miR-29b nanoparticles and delivered the miRNA to the tumour site using a hyaluronic-based hydrogel delivery system. The results showed a significant decrease in tumour burden, increased survival rates, and enhanced regeneration of the damaged bone surrounding the tumour. These findings have the potential to revolutionize osteosarcoma treatment and improve patient outcomes by significantly reducing the primary tumour mass and providing crucial data that will inform the design of future therapies for young patients. Dr. Freeman conducted this work in collaboration with researchers at MIT and Brigham and Women's Hospital. In the coming years, Dr. Freeman is dedicated to building upon this research and advancing this technology toward clinical application. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

This episode is sponsored is by BTG Pharmaceuticals Dr. Michael Bishop is an Assistant Member in the Solid Tumor Division of the Department of Oncology at St. Jude Children’s Hospital in Memphis, TN. His clinical practice focuses primarily on the management of children and young adults with bone and soft tissue sarcomas, and his research interests are dedicated to the development of prospective clinical trials for the treatment of osteosarcoma. Dr. Bishop graduated from the University of Arkansas College of Medicine and completed his pediatric residency at Children’s Mercy Kansas City, and fellowship in pediatric hematology and oncology at Cincinnati Children’s Hospital Medical Center. Dr. Bishop is a member of the Children’s Oncology Group Bone Tumor Committee and is the Study Chair for AOST2032, a prospective trial assessing the feasibility and efficacy of combining a multi-targeted tyrosine kinase inhibitor with chemotherapy for newly diagnosed osteosarcoma. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

This presentation discusses key findings in immunotherapies from the investigator's laboratory as well as those that have shaped the landscape of both human and canine cancers. The information focuses on EGFR and HER2 based immunotherapies, including osteosarcoma, hemangiosarcoma and other cancer types in canine patients. Mechanisms of tumor growth and therapy will also be topics of discussions. --- UCLA (B.A.), Univ Notre Dame (M.S.), University of Oklahoma Health Sciences Center (Ph.D.), Yale University School of Medicine (Professor of Medicine). Dr. Mamula’s interests are in investigating the early events of inflammatory mediated changes in the proteome that intersect with cellular metabolism and with breaking immune tolerance to self proteins. These studies have been applied to the development of novel immune-therapeutic approaches in for antitumor vaccines in EGFR/HER2 expressing cancers, including breast cancer and colon cancer. In particular, the work has evolved to clinical trials in companion canine populations. Overall, it is the goal of Dr. Mamula’s laboratory to understand the mechanisms that may shift the balance of the cellular proteome toward the initiation of anti-self immune responses. In addition, seminal work from the Mamula lab elucidated the proteomics and biochemical forms of autoantigens capable of breaking immunologic tolerance to intracellular autoantigens in type I diabetes (T1D) and in systemic lupus erythematosus (SLE). Simply put, Dr. Mamula examines post translational protein modifications that alter cellular biology and immunity. Recent studies have identified early protein modifications of pancreatic beta cells that are sentinels of early disease and dysfunction of glucose metabolism and insulin release (Nature Comm. 2022). Finally, studies from the Mamula laboratory first demonstrated the ability of B lymphocytes to present autoantigens in the triggering of T cell autoimmunity and in the phenomenon of epitope spreading in lupus autoimmunity, work that contributed to the rationale of B cell mediated therapeutics (Rituximab and Belumimab) in SLE. Dr. Mamula has 113 publications and has mentored over 30 pre-and postdoctoral students and investigators, many of whom have acquired faculty positions as independent investigators at major medical schools, universities, and pharmaceutical industries. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

OsteoWarriors Camille and Mia are joined by members of the MIB Agents Junior Advisory Board to discuss questions submitted by patients, caregivers, clinicians, and researchers. This episode was inspired by the tremendous interest and engagement in the patient panel at the MIB Agents FACTOR 2023 osteosarcoma conference. Camille, Mia, and our Junior Advisory Board discuss many topics including cancer misconceptions, the cringiest things you can say to someone with cancer, what makes them feel supported and seen in their journey by friends and loved ones, making decisions about surgical options, how they cope with scanxiety and preparing for a procedure, and what gets them through their hardest times. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Episode sponsored by BTG Cancer is one of the leading causes of death worldwide. Significant efforts are still necessary to individuate new therapeutic strategies aimed to reduce cancer recurrence and to define new potential adjuvant targets for inhibiting invasion and metastasis, two significant contributors to death among patients. The increasing interest in the employment of nanostructured materials to medicine-related branches is attributable to its unique properties allowing highly efficient drug delivery, molecular sensing applicable in diagnosis, multiplex imaging, or construction of point of care therapeutic devices. This presentation will walk you through our latest developments of functional 3D dual-modality nanostructures for targeted drug delivery of platinum-based complexes. Václav Ranc received his Ph.D. degree in analytical chemistry in 2009 from the Department of Analytical chemistry, Palacky University in Olomouc, Czech Republic under a supervision of Prof. Karel Lemr. He was then employed at the Department of Analytical chemistry, Palacky University, Olomouc as an assistant professor from 2008 to 2010. In 2011, he joined the team of prof. Rainer at the department of medicine at the University of Fribourg in Switzerland as a research scientist. He worked there from 2011-2012. He has been employed at the Regional center of advanced technologies and materials, Palacký University Olomouc since 2012. He has authored or co-authored 74 scientific publications, H index = 27. He is a co-author of three international patents. His research activities are directed towards development of nano-sensors based on the utilization of Surface enhanced Raman spectroscopy and electrochemistry, and synthesis of functionalized nanomaterials for drug delivery systems.

Osteosarcoma Webinar Series: Scott Okuno, MD - SARC Medical Officer and Ann Graham, Executive Director of MIB Agents join us on OsteoBites to discuss how SARC (Sarcoma Alliance for Research through Collaboration) work together to drive collaboration in the sarcoma community and support sarcoma research. -- Dr. Scott Okuno is Professor of Oncology at Mayo Clinic in Rochester, Minnesota. He is a recognized expert in sarcoma and clinical research. Dr. Okuno has been the SARC Medical Officer since 2012. In this role, he provides medical oversight to the day-to-day activities of the SARC clinical trials. Dr. Okuno regularly interacts with the SARC Research Project Management team and the study Principal Investigators to ensure proper study conduct, quality data and overall safety for all SARC clinical trials.  Dr. Okuno was appointed SARC Chief Medical Officer in September 2022, and joined SARC Board of Directors October 2022. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

The Osteosarcoma Institute (OSI) is currently supporting two clinical trials and seven laboratory research projects for osteosarcoma. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chand Khanna, DVM, PhD, Chair of the OSI’s Strategic Advisory Board. Dr. Helman and Dr. Khanna will provide an overview of the OSI’s osteosarcoma research portfolio and explain how the OSI identifies promising osteosarcoma research projects. Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute. Chand Khanna, DVM, PhD is Chief Science Officer with Ethos Veterinary Health, and President of Ethos Discovery(501c3), its incubator of scientific innovation. His responsibility at Ethos Discovery is to develop innovations in the form of novel diagnostics and therapeutics for both human and animal patients afflicted with similar complex disease conditions (i.e., osteosarcoma; so called Comparative Oncology). Dr. Khanna is a veterinary oncologist and both osteosarcoma and metastasis biologist, who has worked in this scientific field for over 20 years, most notably as a senior investigator of the Tumor and Metastasis Biology section of the Pediatric Oncology Branch at the National Cancer Institute and founding Director of its Comparative Oncology Program. Dr. Khanna’s research career has focused on improving the understanding of the biology of metastasis in osteosarcoma and the use of a cross species (mouse, dog, human), Comparative and translational approach to develop novel therapeutics for osteosarcoma metastasis. He serves as the Chair of the Osteosarcoma Institute’s Strategic Advisory Board. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

OsteoWarriors Camille and Gillian are joined by grief coach Lori Krause to discuss what survivor's grief and guilt look like and how to cope and learn to live with these feelings. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Dr. Jeffrey Bryan earned his D.V.M. from the University of California - Davis in 1993. He worked as an Associate Veterinarian from 1993-1995 and served as Medical Director from 1995-2002 of the Irving Street Veterinary Hospital in San Francisco, CA. Bryan then completed a medical oncology residency, a Masters of Biomedical Sciences, and a PhD in Pathobiology at the University of Missouri. He received certification by the American College of Veterinary Internal Medicine in Oncology 2005. He is the Director of the Tom and Betty Scott Endowed Program in Veterinary Oncology, the Director of PET Imaging Center of the University of Missouri, Associate Department Chair for Research, and the Associate Director of Comparative Oncology for Ellis Fischel Cancer Center. Dr. Bryan’s research focuses on comparative examination of cancers in companion animals to better understand cancers in all species. His particular areas of interest are targeted imaging and therapy, epigenetics, and immunotherapy of cancers. He directs the PET Imaging Center, which seeks to develop novel PET imaging agents for cancer diagnosis, localization, and prognostication. He studies DNA methylation of canine non-Hodgkin lymphoma. He studies immunotherapy in companion dogs including investigating fetal microchimerism. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel